## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (46% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($316.49)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch**
- Source: ts2.tech | 20251230T201149 | Somewhat-Bearish | Relevance: 100%
- Amgen shares saw a slight dip after partner Verastem announced the discontinuation of a lung cancer combination study involving Amgen's Lumakras. This development puts more focus on the upcoming year-end updates for Amgen's MariTide obesity and diabetes program, as investors look for new growth drivers amid pressures on existing products. The company's ability to demonstrate strong data for MariTide will be crucial for its future performance against established competitors like Novo Nordisk and Eli Lilly.

**2. Can Amgen's MariTide Take on Leaders in the Obesity Space?**
- Source: The Globe and Mail | 20251230T170838 | Somewhat-Bullish | Relevance: 100%
- Amgen is developing MariTide, a long-acting GLP-1/GIP receptor agonist, as a potential monthly or less frequent treatment for obesity, aiming to compete with current market leaders Eli Lilly and Novo Nordisk. While MariTide offers a differentiated dosing profile, the obesity landscape is rapidly evolving with the introduction of oral GLP-1 therapies and next-generation injectables from competitors. Amgen's financial performance shows its shares have outperformed the industry year-to-date, trading at a discount based on P/E ratio, with elevated EPS estimates for 2025 and 2026.

**3. Amgen Inc.: How a Biotech Veteran Is Rebuilding Its Flagship Pipeline**
- Source: AD HOC NEWS | 20251230T092051 | Bullish | Relevance: 100%
- Amgen Inc. is transforming its growth strategy by shifting focus from mature blockbusters to innovative biologics, biosimilars, and new weight-loss drugs. This evolution aims to build a modular biotech platform with broad therapeutic coverage and multiple revenue streams. The company's future growth hinges on the success of these new assets, particularly MariTide in the obesity market.

**4. Argus Adjusts Price Target on Amgen to $360 From $310, Maintains Buy Rating**
- Source: marketscreener.com | 20251230T125957 | Bullish | Relevance: 100%
- Argus has revised its price target for Amgen (NASDAQ: AMGN) shares upward to $360 from $310, while reiterating its "Buy" rating on the biotechnology company. This adjustment reflects an updated outlook on Amgen's valuation and future prospects. Amgen is a leading biotechnology group, with the majority of its net sales derived from drug sales.

**5. Diversified Trust Co Has $12.05 Million Stock Position in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251230T101400 | Bullish | Relevance: 100%
- Diversified Trust Co increased its stake in Amgen Inc. (NASDAQ:AMGN) by 8.9% in the third quarter, bringing its total holdings to 42,681 shares valued at approximately $12.05 million. This increase follows Amgen's strong Q3 performance, which beat earnings estimates, and a raised FY2025 guidance, contributing to several analyst upgrades and a consensus "Moderate Buy" rating. The company also announced an increased quarterly dividend to $2.52 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 15.0x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $177.0B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 15.0 |
| Current P/E | 15.5 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 51. Volume at 46% of 20MA suggests lack of conviction. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.11% (CS: 47) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.104x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $328.69
- **Stop Loss:** $316.49 (3.7% risk)
- **Target:** $353.09 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 108
- **Position Value:** $35,498.52
- **Portfolio %:** 35.50%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*